Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.05.2026. Verfasst von Nora Mattila und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Helsinki (UH) and Helsinki University Hospital (HUH), Helsinki, Finland. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, CA-19-9 Antigen, Fibrinogen, Factor VIII. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Finnish Foundation for Cardiovascular Research, Academy of Finland, Blood Disease Research Foundation.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is highly thrombogenic and lethal, with rising incidence. Combining carbohydrate antigen (CA) 19–9, fibrinogen, coagulation factor VIII (FVIII), albumin, and alkaline phosphatase (ALP) as a diagnostic panel improves diagnostics. We evaluated the prognostic value of this panel in neoadjuvant therapy (NAT) and upfront surgery (US) treated patients undergoing radical‐intent surgery.
Methods
PDAC patients undergoing radical‐intent surgery with available preoperative coagulation variables were included ( n = 205). Patients with borderline resectable tumors received NAT ( n = 76). The diagnostic panel and a modified panel including only fibrinogen, FVIII, and CA 19–9 were assessed preoperatively and evaluated for disease‐specific and disease‐free survival (DSS and DFS, respectively). Follow‐up was for at least two years or until earlier death.
Results
Preoperative fibrinogen was higher in the US‐treated PDAC patients (US PDAC) than in the NAT‐treated PDAC patients (NAT PDAC) ( p < 0.001). Elevated fibrinogen, FVIII, and CA 19–9 predicted poor DSS individually and as a panel among NAT PDAC; a low modified panel score was associated with better DSS than higher panel scores (HR 7.8, 95% CI 1.7–36.1, p = 0.009).
Conclusions
Preoperatively elevated fibrinogen and FVIII indicated a worse prognosis among NAT patients, especially when combined with CA 19–9 in a panel, possibly referring to treatment response after NAT. Further studies should assess whether preoperative dampening of coagulation activity would improve survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Helsinki (UH) and Helsinki University Hospital (HUH), Helsinki, Finland.
- Department of Hematology, Coagulation Disorders Unit, Comprehensive Cancer Center, Research Program in Systems Oncology, UH and HUH, Helsinki, Finland.
- Translational Cancer Medicine Program, UH and HUH, Helsinki, Finland.
- ICAN Digital Precision Cancer Medicine Flagship, UH, Helsinki, Finland.
ORCID-Profile: Nora Mattila
Förderung
- Finnish Foundation for Cardiovascular Research
- Academy of Finland
- Blood Disease Research Foundation
- Finnish governmental subsidy funding
- Finska Läkaresällskapet
- Sigrid Juséliuksen Säätiö
- Suomen Lääketieteen Säätiö
- Syöpäsäätiö
Zitieren
APA
Mattila, N., Lassila, R., Mustonen, H., Haglund, C., & Seppänen, H. (2026). Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71954
Vancouver
Mattila N, Lassila R, Mustonen H, Haglund C, Seppänen H. Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71954
BibTeX
@article{Mattila2026,
author = {Mattila, Nora and Lassila, Riitta and Mustonen, Harri and Haglund, Caj and Seppänen, Hanna},
title = {Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19–9 as a Tool for Prognostic Evaluation in Neoadjuvant‐Treated Pancreatic Ductal Adenocarcinoma},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71954}
}
EUVIMED